Independent fund research. Built on SEC filings.

How we research funds

Fund comparison

IBB vs. PBE: which is better?

Bottom line

IBB vs PBE: the short answer

IBB (iShares Biotechnology ETF) and PBE (Invesco Biotechnology & Genome ETF) are quite different portfolios: only about 36% of their top holdings (by weight) are shared.

But IBB is far broader, holding 254 positions to 33 for PBE, so beyond the top names it adds exposure PBE doesn't have.

IBB is cheaper at 0.44% vs 0.59% — a difference of $15 a year per $10,000 invested.

Over five years, PBE returned +3.4% a year vs +2.5% for IBB.

Updated Nov 19, 2026

IBB vs PBE side by side

IBBPBE
TypeETFETF
Fund familyiSharesInvesco
CategoryTechnology SectorTechnology Sector
Expense ratio0.44%0.59%
Annual cost per $10k$44$59
10-yr cost on $10k (prospectus)$555$738
Max front loadNoneNone
12b-1 fee0%—
1-yr return+28.0%+24.7%
5-yr return (annualized)+2.5%+3.4%
10-yr return (annualized)+4.4%+5.2%
Best quarter+26.8%+25.3%
Worst quarter−22.9%−24.3%
Net assets (fund)$5.9B$281.9M
Number of holdings25433
Portfolio turnover27%103%
Returns as ofDec 31, 2025Dec 31, 2025

Source: SEC Form N-PORT and fund prospectuses

Year-by-year returns

YearIBBPBEDifference
2025+28.0%+24.7%+3.3%
2024−2.4%+1.1%−3.5%
2023+3.6%+3.7%−0.1%
2022−13.6%−10.8%−2.8%
2021+1.0%+1.6%−0.6%
2020+25.9%+25.5%+0.4%
2019+24.8%+18.3%+6.5%
2018−9.1%+0.2%−9.4%
2017+21.2%+22.4%−1.2%
2016−21.5%−23.0%+1.5%

Source: Fund prospectus bar charts

Holdings overlap

12 of IBB's top 25 holdings also appear in PBE's top 25.

Shared top holdings
HoldingIBBPBE
Vertex Pharmaceuticals, Inc.7.66%4.99%
Gilead Sciences, Inc.7.52%4.43%
Amgen, Inc.7.50%5.22%
Regeneron Pharmaceuticals, Inc.5.70%5.47%
Alnylam Pharmaceuticals, Inc.5.68%3.17%
Biogen, Inc.2.03%4.79%
United Therapeutics Corp.1.82%4.08%
Incyte Corp.1.62%3.06%
Illumina, Inc.1.41%3.51%
Neurocrine Biosciences, Inc.1.34%2.66%
Exelixis, Inc.1.07%2.64%
BioMarin Pharmaceutical, Inc.1.02%2.82%

Source: SEC Form N-PORT

IBB top 10

  1. BlackRock Funds III — 13.18%
  2. Vertex Pharmaceuticals, Inc. — 7.66%
  3. Gilead Sciences, Inc. — 7.52%
  4. Amgen, Inc. — 7.50%
  5. Regeneron Pharmaceuticals, Inc. — 5.70%
  6. Alnylam Pharmaceuticals, Inc. — 5.68%
  7. IQVIA Holdings, Inc. — 3.18%
  8. Argenx SE — 3.15%
  9. Insmed, Inc. — 2.95%
  10. Mettler-Toledo International, Inc. — 2.49%

PBE top 10

  1. Invesco Private Prime Fund — 12.89%
  2. Regeneron Pharmaceuticals, Inc. — 5.47%
  3. Amgen Inc. — 5.22%
  4. CareDx, Inc. — 5.04%
  5. Vertex Pharmaceuticals Inc. — 4.99%
  6. Invesco Private Government Fund — 4.97%
  7. Royalty Pharma PLC — 4.94%
  8. Biogen Inc. — 4.79%
  9. Gilead Sciences, Inc. — 4.43%
  10. United Therapeutics Corp. — 4.08%

FAQ

What is the difference between IBB and PBE?
IBB (iShares Biotechnology ETF) and PBE (Invesco Biotechnology & Genome ETF) are quite different portfolios: only about 36% of their top holdings (by weight) are shared. But IBB is far broader, holding 254 positions to 33 for PBE, so beyond the top names it adds exposure PBE doesn't have.
Which is cheaper, IBB or PBE?
IBB has the lower expense ratio (0.44%).
Should I own both IBB and PBE?
Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.

Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.